Readjudication

$title =

Plozasiran

;

$content = [

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

48 week

TG 150-499 + LDL >70

3:1 ratio to receive plozasiran

subcutaneous injection of plozasiran (10 mg, 25 mg, or 50 mg)quarterly

  • 10mg:−49.8 percentage points
  • 25mg:−56.0 percentage points
  • 50mg:−62.4 percentage points
  • 50mg q6mo: −44.2 percentage points

AE:

Worsening glycemic control was observed in 10% of the participants receiving placebo, 12% of those receiving the 10-mg-quarterly dose, 7% of those receiving the 25-mg-quarterly dose, 20% of those receiving the 50-mg-quarterly dose, and 21% of those receiving the 50-mg-half-yearly dose.

The trial did not assess the effect of plozasiran
on the risk of atherosclerotic cardiovascular
disease, so the effect of the drug on clinical
outcomes is unknown.

];

$date =

;

$category =

;

$author =

Anthony Taylor

;

$previous =

;

$next =

;